Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Exclusion Criteria

• •For Groups A and B
• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
• •Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine(s).
• •Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliovirus, and/or Streptococcus pneumoniae; more than one previous dose of hepatitis B vaccine.
• •History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, hepatitis B, poliovirus, and/or Streptococcus pneumoniae disease.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including dry natural latex rubber.
• •Major congenital defects or serious chronic illness.
• •History of any neurologic disorders or seizures.
• •Acute disease at time of enrollment.
• •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
• •For Group C
• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.
• •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.
• •Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the dose of study vaccine.
• •Previous vaccination against Neisseria meningitidis.
• •History of Neisseria meningitidis disease.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including dry natural latex rubber
• •Major congenital defects or serious chronic illness.
• •Acute disease at time of enrollment.
• •Administration of immunoglobulins and/or any blood products within the 3 months preceding vaccination or planned administration during the study period.